# Recombinant Protein Technical Manual

## Recombinant Mouse TNFRSF17/BCMA Protein (His & Fc Tag)(Active)

**RPES0449**

## Product Data:

**Product SKU:** RPES0449

**Size:** 50µg

**Species**: Mouse

**Expression host:** HEK293 Cells

**Uniprot:** NP_035738.1

## Protein Information:

| | |
|---|---|
| **Molecular Mass:** | 33.7 kDa |
| **AP Molecular Mass:** | 35-48 kDa |
| **Tag:** | C-His-Fc |
| **Bio-activity:** | Measured by its binding ability in a functional ELISA. Immobilized human BAFF at 10 µg/ml (100 µl/well) can bind mouse BCMA-Fch, The EC50 of mouse BCMA-Fch is 0.02-0.06 µg/mL. |
| **Purity:** | > 90 % as determined by SDS-PAGE |
| **Endotoxin:** | < 1.0 EU per µg of the protein as determined by the LAL method. |
| **Storage:** | Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| **Shipping:** | This product is provided as lyophilized powder which is shipped with ice packs. |
| **Formulation:** | Lyophilized from sterile PBS, pH 7.4 |
| **Reconstitution:** | Please refer to the printed manual for detailed information. |
| **Application:** | Functional ELISA |
| **Synonyms:** | Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; Tnfrsf17;BCM;BCMA;Tnfrsf13;Tnfrsf13a |

## Immunogen Information:

**Sequence:** Met 1-Thr 49

## Background:

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.